The myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic disorders characterized by cytopenias, dysplasia in one or more myeloid lineages, and the potential for development of acute myeloid leukemia. These disorders primarily affect older adults. The NCCN Clinical Practice Guidelines in Oncology for MDS provide recommendations on the diagnostic evaluation and classification of MDS, risk evaluation according to established prognostic assessment tools (including the new revised International Prognostic Scoring System), treatment options according to risk categories, and management of related anemia.

  • 1.

    National Cancer Institute. SEER Cancer Statistics Review 1975-2009: myelodysplastic syndromes (MDS) chronic myeloproliferative disorders (CMD) and chronic myelomonocytic leukemia (CMML). 2010. Available at: http://seer.cancer.gov/csr/1975_2007/results_merged/sect_30_mds.pdf. Accessed April 2013.

    • Search Google Scholar
    • Export Citation
  • 2.

    MaXDoesMRazaAMayneST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer2007;109:15361542.

  • 3.

    GreenbergP. The myelodysplastic syndromes. In: HoffmanRBenzEShattilS. Hematology: Basic Principles and Practice. 3rd ed.New York, NY: Churchill Livingstone; 2000:11061129.

    • Search Google Scholar
    • Export Citation
  • 4.

    SwerdlowSCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France: IARC; 2008.

  • 5.

    BrunningROraziAGermingU. Myelodysplastic syndromes/neoplasms. In: SwerdlowSHCampoEHarrisNL eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France: IARC Press; 2008:88103.

    • Search Google Scholar
    • Export Citation
  • 6.

    VardimanJWThieleJArberDA. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood2009;114:937951.

    • Search Google Scholar
    • Export Citation
  • 7.

    BrunningRBennettJFlandrinG. Myelodysplastic syndromes. In: JaffeEHarrisNSteinH eds. WHO Classification of Tumours. Pathology and Genetics of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:6173.

    • Search Google Scholar
    • Export Citation
  • 8.

    HarrisNLJaffeESDieboldJ. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol1999;17:38353849.

    • Search Google Scholar
    • Export Citation
  • 9.

    VardimanJWHarrisNLBrunningRD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood2002;100:22922302.

  • 10.

    GreenbergPCoxCLeBeauMM. International scoring system for evaluating prognosis in myelodysplastic syndromes [published correction appears in Blood 1998;91:1100]. Blood1997;89:20792088.

    • Search Google Scholar
    • Export Citation
  • 11.

    ListADewaldGBennettJ. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med2006;355:14561465.

  • 12.

    VardimanJWBennettJMBainBJ. Myelodysplastic/myeloproliferative neoplasms. In: SwerdlowSHCampoEHarrisNL eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.Lyon, France: IARC; 2008:7586.

    • Search Google Scholar
    • Export Citation
  • 13.

    VardimanJWBennettJMBainBJ. Myelodysplastic/myeloproliferative neoplasm, unclassifiable. In: SwerdlowSHCampoEHarrisNL eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed.Lyon, France: IARC; 2008:8586.

    • Search Google Scholar
    • Export Citation
  • 14.

    AlbitarMManshouriTShenY. Myelodysplastic syndrome is not merely “preleukemia”. Blood2002;100:791798.

  • 15.

    GreenbergPAndersonJde WitteT. Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. J Clin Oncol2000;18:34473452.

    • Search Google Scholar
    • Export Citation
  • 16.

    ArberDABrunningRDOraziA. Acute myeloid leukaemia with myelodysplasia-related changes. In Chapter 6: Acute myeloid leukemia and related precursor neoplasms. In: SwerdlowSCampoEHarrisNL eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues4th ed.Lyon, France: IARC Press; 2008:124126.

    • Search Google Scholar
    • Export Citation
  • 17.

    GermingUGattermannNStruppC. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res2000;24:983992.

    • Search Google Scholar
    • Export Citation
  • 18.

    GermingUStruppCKuendgenA. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol2006;132:162167.

    • Search Google Scholar
    • Export Citation
  • 19.

    GermingUStruppCKuendgenA. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica2006;91:15961604.

    • Search Google Scholar
    • Export Citation
  • 20.

    MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:75947603.

    • Search Google Scholar
    • Export Citation
  • 21.

    Muller-BerndorffHHaasPSKunzmannR. Comparison of five prognostic scoring systems, the French-American-British (FAB) and World Health Organization (WHO) classifications in patients with myelodysplastic syndromes: results of a single-center analysis. Ann Hematol2006;85:502513.

    • Search Google Scholar
    • Export Citation
  • 22.

    ValentPHornyHPBennettJM. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res2007;31:727736.

    • Search Google Scholar
    • Export Citation
  • 23.

    JafarzadehAPoorgholamiMIzadiN. Immunological and hematological changes in patients with hyperthyroidism or hypothyroidism. Clin Invest Med2010;33:E271279.

    • Search Google Scholar
    • Export Citation
  • 24.

    DunnDETanawattanacharoenPBoccuniP. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med1999;131:401408.

    • Search Google Scholar
    • Export Citation
  • 25.

    SaunthararajahYNakamuraRNamJM. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood2002;100:15701574.

    • Search Google Scholar
    • Export Citation
  • 26.

    BorowitzMJCraigFEDigiuseppeJA. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom2010;78:211230.

    • Search Google Scholar
    • Export Citation
  • 27.

    TakedaJMiyataTKawagoeK. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell1993;73:703711.

    • Search Google Scholar
    • Export Citation
  • 28.

    WareRERosseWFHowardTA. Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. Blood1994;83:24182422.

  • 29.

    BattiwallaMHepgurMPanD. Multiparameter flow cytometry for the diagnosis and monitoring of small GPI-deficient cellular populations. Cytometry B Clin Cytom2010;78:348356.

    • Search Google Scholar
    • Export Citation
  • 30.

    KussickSJFrommJRRossiniA. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol2005;124:170181.

    • Search Google Scholar
    • Export Citation
  • 31.

    van de LoosdrechtAAAlhanCBeneMC. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica2009;94:11241134.

    • Search Google Scholar
    • Export Citation
  • 32.

    WestersTMIrelandRKernW. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia2012;26:17301741.

    • Search Google Scholar
    • Export Citation
  • 33.

    WoodBL. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia. Clin Lab Med2007;27:551575vii.

    • Search Google Scholar
    • Export Citation
  • 34.

    WoodBLArrozMBarnettD. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom2007;72(Suppl 1):S1422.

    • Search Google Scholar
    • Export Citation
  • 35.

    Della PortaMGPiconeCPascuttoC. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica2012;97:12091217.

    • Search Google Scholar
    • Export Citation
  • 36.

    ChanWCFoucarKMoriceWGCatovskyD. T-cell large granular lymphocytic leukemia. In: SwerdlowSHCampoEHarrisNL eds. WHO classification of tumours of haematopoietic and lymphoid tissues4th ed.Lyon, France: IARC; 2008:272273.

    • Search Google Scholar
    • Export Citation
  • 37.

    DuHYPumboEIvanovichJ. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood2009;113:309316.

    • Search Google Scholar
    • Export Citation
  • 38.

    VulliamyTJMarroneAKnightSW. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood2006;107:26802685.

    • Search Google Scholar
    • Export Citation
  • 39.

    AlterBPBaerlocherGMSavageSA. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood2007;110:14391447.

    • Search Google Scholar
    • Export Citation
  • 40.

    MichaudJWuFOsatoM. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood2002;99:13641372.

    • Search Google Scholar
    • Export Citation
  • 41.

    SongWJSullivanMGLegareRD. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet1999;23:166175.

    • Search Google Scholar
    • Export Citation
  • 42.

    LiewEOwenC. Familial myelodysplastic syndromes: a review of the literature. Haematologica2011;96:15361542.

  • 43.

    QuentinSCuccuiniWCeccaldiR. Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood2011;117:e161170.

    • Search Google Scholar
    • Export Citation
  • 44.

    FadilahSACheongSKRoslanH. GATA-1 and GATA-2 gene expression is related to the severity of dysplasia in myelodysplastic syndrome. Leukemia2002;16:15631565.

    • Search Google Scholar
    • Export Citation
  • 45.

    HahnCNChongCECarmichaelCL. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet2011;43:10121017.

    • Search Google Scholar
    • Export Citation
  • 46.

    BaxterEJKulkarniSVizmanosJL. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol2003;120:251256.

    • Search Google Scholar
    • Export Citation
  • 47.

    SteerEJCrossNC. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol2002;107:113122.

    • Search Google Scholar
    • Export Citation
  • 48.

    ApperleyJFGardembasMMeloJV. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med2002;347:481487.

    • Search Google Scholar
    • Export Citation
  • 49.

    DavidMCrossNCBurgstallerS. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood2007;109:6164.

    • Search Google Scholar
    • Export Citation
  • 50.

    MagnussonMKMeadeKENakamuraR. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood2002;100:10881091.

    • Search Google Scholar
    • Export Citation
  • 51.

    SteensmaDPDewaldGWLashoTL. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes. Blood2005;106:1207209.

    • Search Google Scholar
    • Export Citation
  • 52.

    SzpurkaHTiuRMurugesanG. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood2006;108:21732181.

    • Search Google Scholar
    • Export Citation
  • 53.

    OgataKNakamuraKYokoseN. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood2002;100:38873896.

    • Search Google Scholar
    • Export Citation
  • 54.

    WellsDABeneschMLokenMR. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood2003;102:394403.

    • Search Google Scholar
    • Export Citation
  • 55.

    GreggXTReddyVPrchalJT. Copper deficiency masquerading as myelodysplastic syndrome. Blood2002;100:14931495.

  • 56.

    HaddadASSubbiahVLichtinAE. Hypocupremia and bone marrow failure. Haematologica2008;93:e15.

  • 57.

    KocaEBuyukasikYCetinerD. Copper deficiency with increased hematogones mimicking refractory anemia with excess blasts. Leuk Res2008;32:495499.

    • Search Google Scholar
    • Export Citation
  • 58.

    ProdanCIBottomleySSVincentAS. Hypocupremia associated with prior vitamin B12 deficiency. Am J Hematol2007;82:288290.

  • 59.

    SanzGFSanzMAGreenbergPL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica1998;83:358368.

  • 60.

    BennettJMCatovskyDDanielMT. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol1994;87:746754.

    • Search Google Scholar
    • Export Citation
  • 61.

    MalcovatiLGermingUKuendgenA. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol2007;25:35033510.

    • Search Google Scholar
    • Export Citation
  • 62.

    KaoJMMcMillanAGreenbergPL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol2008;83:765770.

    • Search Google Scholar
    • Export Citation
  • 63.

    AlessandrinoEPDella PortaMGBacigalupoA. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood2008;112:895902.

    • Search Google Scholar
    • Export Citation
  • 64.

    CermakJKacirkovaPMikulenkovaDMichalovaK. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res2009;33:14691474.

    • Search Google Scholar
    • Export Citation
  • 65.

    ParkMJKimHJKimSH. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome? External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS. Eur J Haematol2008;81:364373.

    • Search Google Scholar
    • Export Citation
  • 66.

    MalcovatiLDella PortaMGStruppC. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica2011;96:14331440.

    • Search Google Scholar
    • Export Citation
  • 67.

    GreenbergPLTuechlerHSchanzJ. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood2012;120:24542465.

    • Search Google Scholar
    • Export Citation
  • 68.

    SchanzJTuchlerHSoleF. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol2012;30:820829.

    • Search Google Scholar
    • Export Citation
  • 69.

    AdesLLamarqueMRaynaudS. Revised-IPSS (IPSS-R) is a powerful tool to evaluate the outcome of mds patient treated with azacitidine (AZA): the Groupe Francophone Des Myelodysplasies (GFM) experience [abstract]. Blood2012;120:Abstract 422.

    • Search Google Scholar
    • Export Citation
  • 70.

    CermakJMikulenkovaDBrezinovaJMichalovaK. A reclassification of myelodysplastic syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall survival. A retrospective analysis of 49 patients [abstract]. Blood2012;120:Abstract 4957.

    • Search Google Scholar
    • Export Citation
  • 71.

    MessaEGioiaDEvangelistaA. High predictive value of the revised International Prognostic Scoring System (IPSS-R): an external analysis of 646 patients from a multiregional italian MDS registry [abstract]. Blood2012;120:Abstract 1702.

    • Search Google Scholar
    • Export Citation
  • 72.

    MishraAAliNHACorrales-YepezM. Validation of the revised International Prognostic Scoring System (R-IPSS) for patients with myelodysplastic syndromes: therapeutic implications [abstract]. Blood2012;120:Abstract 2816.

    • Search Google Scholar
    • Export Citation
  • 73.

    ValcarcelDSanzGOrtegaM. Identification of poor risk patients in low and intermediate-1 (Int-1) IPSS MDS with the new IPSSR index and comparison with other prognostic indexes. A study by the Spanish Group of MDS (GESMD) [abstract]. Blood2012;120:Abstract 702.

    • Search Google Scholar
    • Export Citation
  • 74.

    WarlickEDHirschBANguyenPL. Comparison of IPSS and IPSS-R scoring in a population based myelodysplastic syndromes (MDS) study [abstract]. Blood2012;120:Abstract 3841.

    • Search Google Scholar
    • Export Citation
  • 75.

    Garcia-ManeroGShanJFaderlS. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia2008;22:538543.

  • 76.

    BejarRStevensonKECaugheyBA. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol2012;30:33763382.

    • Search Google Scholar
    • Export Citation
  • 77.

    KomrokjiRSCorrales-YepezMAl AliNH. Validation of the lower risk MD Anderson prognostic scoring system for patients with myelodysplastic syndromes [abstract]. Blood2012;120:Abstract 3826.

    • Search Google Scholar
    • Export Citation
  • 78.

    SekeresMAElsonPTiuRV. Validating the lower-risk MD Anderson prognostic scoring system (LR-PSS) and the revised International Prognostic Scoring System (IPSS-R) for patients with myelodysplastic syndromes [abstract]. Blood2011;118:Abstract 1720.

    • Search Google Scholar
    • Export Citation
  • 79.

    ChesonBDBennettJMKantarjianH. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood2000;96:36713674.

    • Search Google Scholar
    • Export Citation
  • 80.

    ChesonBDGreenbergPLBennettJM. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood2006;108:419425.

    • Search Google Scholar
    • Export Citation
  • 81.

    GreenbergPBaerMBennettJ. NCCN Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes. Version 12001. In: The Complete Library of NCCN Guidelines [CD-ROM]. Rockledge, PA: NCCN: 2001.

    • Search Google Scholar
    • Export Citation
  • 82.

    GreenbergP. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. International Journal of Pediatric Hematology/Oncology1997;4:231238.

    • Search Google Scholar
    • Export Citation
  • 83.

    Hellstrom-LindbergEAhlgrenTBeguinY. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood1998;92:6875.

    • Search Google Scholar
    • Export Citation
  • 84.

    JaderstenMMalcovatiLDybedalI. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol2008;26:36073613.

    • Search Google Scholar
    • Export Citation
  • 85.

    KelaidiCBeyne-RauzyOBraunT. High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM. Ann Hematol2013;92:621631.

    • Search Google Scholar
    • Export Citation
  • 86.

    KelaidiCParkSBrechignacS. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res2008;32:10491053.

    • Search Google Scholar
    • Export Citation
  • 87.

    ParkSGrabarSKelaidiC. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood2008;111:574582.

    • Search Google Scholar
    • Export Citation
  • 88.

    TehranchiRFadeelBSchmidt-MendeJ. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res2005;11:62916299.

    • Search Google Scholar
    • Export Citation
  • 89.

    HouwerzijlEJBlomNRvan der WantJJ. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood2005;105:34723479.

    • Search Google Scholar
    • Export Citation
  • 90.

    TamuraHOgataKLuoS. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol1998;103:778784.

    • Search Google Scholar
    • Export Citation
  • 91.

    ZwierzinaHRollinger-HolzingerINuesslerV. Endogenous serum thrombopoietin concentrations in patients with myelodysplastic syndromes. Leukemia1998;12:5964.

    • Search Google Scholar
    • Export Citation
  • 92.

    GreenbergPLGarcia-ManeroGMooreM. A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. Leuk Lymphoma2013;54:321328.

    • Search Google Scholar
    • Export Citation
  • 93.

    KantarjianHFenauxPSekeresMA. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol2010;28:437444.

    • Search Google Scholar
    • Export Citation
  • 94.

    KantarjianHMGilesFJGreenbergPL. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood2010;116:31633170.

    • Search Google Scholar
    • Export Citation
  • 95.

    SekeresMAKantarjianHFenauxP. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer2011;117:9921000.

    • Search Google Scholar
    • Export Citation
  • 96.

    WangESLyonsRMLarsonRA. A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. J Hematol Oncol2012;5:71.

    • Search Google Scholar
    • Export Citation
  • 97.

    MavroudiIPyrovolakiKPavlakiK. Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome. Leuk Res2011;35:323328.

    • Search Google Scholar
    • Export Citation
  • 98.

    WillBKawaharaMLucianoJP. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood2009;114:38993908.

    • Search Google Scholar
    • Export Citation
  • 99.

    HashimotoSTobaKFuseI. Thrombopoietin activates the growth of megakaryoblasts in patients with chronic myeloproliferative disorders and myelodysplastic syndrome. Eur J Haematol2000;64:225230.

    • Search Google Scholar
    • Export Citation
  • 100.

    LuoSSOgataKYokoseN. Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells2000;18:112119.

    • Search Google Scholar
    • Export Citation
  • 101.

    FenauxPMuftiGJHellstrom-LindbergE. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol2009;10:223232.

    • Search Google Scholar
    • Export Citation
  • 102.

    KantarjianHIssaJPRosenfeldCS. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer2006;106:17941803.

    • Search Google Scholar
    • Export Citation
  • 103.

    LubbertMSuciuSBailaL. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol2011;29:19871996.

    • Search Google Scholar
    • Export Citation
  • 104.

    SilvermanLRDemakosEPPetersonBL. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol2002;20:24292440.

    • Search Google Scholar
    • Export Citation
  • 105.

    SilvermanLRMcKenzieDRPetersonBL. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol2006;24:38953903.

    • Search Google Scholar
    • Export Citation
  • 106.

    SilvermanLRFenauxPMuftiGJ. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes. Cancer2011;117:26972702.

    • Search Google Scholar
    • Export Citation
  • 107.

    LyonsRMCosgriffTMModiSS. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol2009;27:18501856.

    • Search Google Scholar
    • Export Citation
  • 108.

    MartinMGWalgrenRAProcknowE. A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol2009;84:560564.

    • Search Google Scholar
    • Export Citation
  • 109.

    LubbertMWijermansPKunzmannR. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2’-deoxycytidine. Br J Haematol2001;114:349357.

    • Search Google Scholar
    • Export Citation
  • 110.

    WijermansPLubbertMVerhoefG. Low-dose 5-aza-2’-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol2000;18:956962.

    • Search Google Scholar
    • Export Citation
  • 111.

    SabaHRosenfeldCIssaJ. First report of the phase III north American trial of decitabine in advanced myelodysplastic syndrome (MDS) [abstract]. Blood2004;104:Abstract 67.

    • Search Google Scholar
    • Export Citation
  • 112.

    van den BoschJLubbertMVerhoefGWijermansPW. The effects of 5-aza-2’-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res2004;28:785790.

    • Search Google Scholar
    • Export Citation
  • 113.

    SabaHLubbertMWijermansPW. Response rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS) [abstract]. Blood2005;106:Abstract 2515.

    • Search Google Scholar
    • Export Citation
  • 114.

    KantarjianHMO’BrienSShanJ. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer2007;109:265273.

    • Search Google Scholar
    • Export Citation
  • 115.

    KantarjianHOkiYGarcia-ManeroG. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood2007;109:5257.

    • Search Google Scholar
    • Export Citation
  • 116.

    DamajGDuhamelARobinM. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. J Clin Oncol2012;30:45334540.

    • Search Google Scholar
    • Export Citation
  • 117.

    FieldTPerkinsJHuangY. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant2010;45:255260.

    • Search Google Scholar
    • Export Citation
  • 118.

    GerdsATGooleyTAEsteyEH. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant2012;18:12111218.

    • Search Google Scholar
    • Export Citation
  • 119.

    LubbertMBertzHRuterB. Non-intensive treatment with low-dose 5-aza-2’-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant2009;44:585588.

    • Search Google Scholar
    • Export Citation
  • 120.

    DeegHJGotlibJBeckhamC. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia2002;16:162164.

    • Search Google Scholar
    • Export Citation
  • 121.

    DeegHJJiangPYHolmbergLA. Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res2004;28:11771180.

    • Search Google Scholar
    • Export Citation
  • 122.

    JonásováANeuwirtováRCermákJ. 164 Promising cyclosporin a therapy for myelodysplastic syndrome. Leukemia Research1997;21:S53.

  • 123.

    MolldremJJCaplesMMavroudisD. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol1997;99:699705.

  • 124.

    RazaAMeyerPDuttD. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood2001;98:958965.

    • Search Google Scholar
    • Export Citation
  • 125.

    StruppCGermingUAivadoM. Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia2002;16:16.

  • 126.

    SloandEMWuCOGreenbergP. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol2008;26:25052511.

    • Search Google Scholar
    • Export Citation
  • 127.

    ScheinbergPNunezOWeinsteinB. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med2011;365:430438.

  • 128.

    ScheinbergPWuCOScheinbergP. A randomized trial of horse versus rabbit antithymocyte globulin in severe acquired aplastic anemia [abstract]. Blood2010;116:Abstract LBA-4.

    • Search Google Scholar
    • Export Citation
  • 129.

    StadlerMGermingUKlicheKO. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia2004;18:460465.

    • Search Google Scholar
    • Export Citation
  • 130.

    ListAKurtinSRoeDJ. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med2005;352:549557.

  • 131.

    NimerSD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol2006;24:25762582.

    • Search Google Scholar
    • Export Citation
  • 132.

    FenauxPGiagounidisASelleslagD. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood2011;118:37653776.

    • Search Google Scholar
    • Export Citation
  • 133.

    KuendgenALausekerMListAF. Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with low- or intermediate-1-risk MDS with del(5q): a comparative analysis. Leukemia2013;27:10721079.

    • Search Google Scholar
    • Export Citation
  • 134.

    RazaAReevesJAFeldmanEJ. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood2008;111:8693.

    • Search Google Scholar
    • Export Citation
  • 135.

    TricotGBoogaertsMA. The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol1986;63:477483.

    • Search Google Scholar
    • Export Citation
  • 136.

    EsteyEHThallPFCortesJE. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood2001;98:35753583.

    • Search Google Scholar
    • Export Citation
  • 137.

    SonneveldPvan DongenJJHagemeijerA. High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia1993;7:963969.

    • Search Google Scholar
    • Export Citation
  • 138.

    AdvaniRSabaHITallmanMS. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood1999;93:787795.

    • Search Google Scholar
    • Export Citation
  • 139.

    WattelESolaryEHecquetB. Quinine improves results of intensive chemotherapy (IC) in myelodysplastic syndromes (MDS) expressing P-glycoprotein (PGP). Updated results of a randomized study. Groupe Francais des Myelodysplasies (GFM) and Groupe GOELAMS. Adv Exp Med Biol1999;457:3546.

    • Search Google Scholar
    • Export Citation
  • 140.

    GreenbergPLLeeSJAdvaniR. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). J Clin Oncol2004;22:10781086.

    • Search Google Scholar
    • Export Citation
  • 141.

    AndersonJEAppelbaumFRFisherLD. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood1993;82:677681.

    • Search Google Scholar
    • Export Citation
  • 142.

    De WitteTZwaanFHermansJ. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol1990;74:151155.

    • Search Google Scholar
    • Export Citation
  • 143.

    DemuynckHVerhoefGEZacheeP. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant1996;17:745751.

    • Search Google Scholar
    • Export Citation
  • 144.

    JuradoMDeegHJStorerB. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. Biol Blood Marrow Transplant2002;8:161169.

    • Search Google Scholar
    • Export Citation
  • 145.

    KerbauyDMChyouFGooleyT. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant2005;11:713720.

    • Search Google Scholar
    • Export Citation
  • 146.

    NevillTJFungHCShepherdJD. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood1998;92:19101917.

    • Search Google Scholar
    • Export Citation
  • 147.

    ScottBLSandmaierBMStorerB. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia2006;20:128135.

    • Search Google Scholar
    • Export Citation
  • 148.

    WallenHGooleyTADeegHJ. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol2005;23:34393446.

    • Search Google Scholar
    • Export Citation
  • 149.

    AndersonJThomasEDAnasettiC. Unrelated donor marrow transplantation for myelodysplasia (MDS) and MDS-related acute myeloid leukaemia. Br J Haematol1996;93:5967.

    • Search Google Scholar
    • Export Citation
  • 150.

    Castro-MalaspinaHHarrisREGajewskiJ. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood2002;99:19431951.

    • Search Google Scholar
    • Export Citation
  • 151.

    DeegH. Optimization of transplant regimens for patients with myelodysplastic syndromes (MDS). In: Hematology 2005: American Society of Hematology Education Program Book: Washington, DC: American Society of Hematology; 2005;167173.

    • Search Google Scholar
    • Export Citation
  • 152.

    DeegHJScottBLFangM. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood2012;120:13981408.

    • Search Google Scholar
    • Export Citation
  • 153.

    de LimaMAnagnostopoulosAMunsellM. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood2004;104:865872.

    • Search Google Scholar
    • Export Citation
  • 154.

    GiraltSEsteyEAlbitarM. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood1997;89:45314536.

    • Search Google Scholar
    • Export Citation
  • 155.

    LitzowMRTarimaSPerezWS. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood2010;115:18501857.

    • Search Google Scholar
    • Export Citation
  • 156.

    McCluneBLWeisdorfDJPedersenTL. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol2010;28:18781887.

    • Search Google Scholar
    • Export Citation
  • 157.

    SorrorMLSandmaierBMStorerBE. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol2007;25:42464254.

    • Search Google Scholar
    • Export Citation
  • 158.

    De WitteTSuciuSVerhoefG. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood2001;98:23262331.

    • Search Google Scholar
    • Export Citation
  • 159.

    FukumotoJSGreenbergPL. Management of patients with higher risk myelodysplastic syndromes. Crit Rev Oncol Hematol2005;56:179192.

  • 160.

    AlyeaEPKimHTHoV. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood2005;105:18101814.

    • Search Google Scholar
    • Export Citation
  • 161.

    CutlerCSLeeSJGreenbergP. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood2004;104:579585.

    • Search Google Scholar
    • Export Citation
  • 162.

    LaportGGSandmaierBMStorerBE. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant2008;14:246255.

    • Search Google Scholar
    • Export Citation
  • 163.

    McCluneBWeisdorfDDiPersioJ. Non-myeloablative hematopoietic stem cell transplantation in older patients with AML and MDS: results from the Center for International Blood and Marrow Transplant Research (CIBMTR) [abstract]. Blood2008;112:Abstract 346.

    • Search Google Scholar
    • Export Citation
  • 164.

    Kindwall-KellerTIsolaLM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant2009;43:597609.

  • 165.

    OlianskyDMAntinJHBennettJM. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant2009;15:137172.

    • Search Google Scholar
    • Export Citation
  • 166.

    DeegHSandmaierBM. Who is fit for allogeneic transplantation?Blood2010;116:47624770.

  • 167.

    BeranMShenYKantarjianH. High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens. Cancer2001;92:19992015.

    • Search Google Scholar
    • Export Citation
  • 168.

    WijermansPSuciuSBailaL. Low dose decitabine versus best supportive care in elderly patients with intermediate or high risk MDS not eligible for intensive chemotherapy: final results of the randomized phase III study (06011) of the EORTC leukemia and German MDS study groups [abstract]. Blood2008;112:Abstract 226.

    • Search Google Scholar
    • Export Citation
  • 169.

    JacobsAJanowska-WieczorekACaroJ. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol1989;73:3639.

  • 170.

    Hellstrom-LindbergE. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol1995;89:6771.

    • Search Google Scholar
    • Export Citation
  • 171.

    NegrinRSSteinRDohertyK. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood1996;87:40764081.

    • Search Google Scholar
    • Export Citation
  • 172.

    CasadevallNDurieuxPDuboisS. Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood2004;104:321327.

    • Search Google Scholar
    • Export Citation
  • 173.

    Hellstrom-LindbergENegrinRSteinR. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol1997;99:344351.

    • Search Google Scholar
    • Export Citation
  • 174.

    SpiritiMALatagliataRNiscolaP. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol2005;84:167176.

    • Search Google Scholar
    • Export Citation
  • 175.

    Hellstrom-LindbergEGulbrandsenNLindbergG. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol2003;120:10371046.

    • Search Google Scholar
    • Export Citation
  • 176.

    MannoneLGardinCQuarreMC. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol2006;133:513519.

    • Search Google Scholar
    • Export Citation
  • 177.

    MustoPLanzaFBalleariE. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol2005;128:204209.

    • Search Google Scholar
    • Export Citation
  • 178.

    GiraldoPNomdedeuBLoscertalesJ. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer2006;107:28072816.

    • Search Google Scholar
    • Export Citation
  • 179.

    StasiRAbruzzeseELanzettaG. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol2005;16:19211927.

    • Search Google Scholar
    • Export Citation
  • 180.

    GreenbergPLSunZMillerKB. Treatment of myelodysplastic syndromes patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase III trial by the Eastern Cooperative Oncology Group (E1996). Blood2009;114:23922400.

    • Search Google Scholar
    • Export Citation
  • 181.

    KornblithABHerndonJEIISilvermanLR. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol2002;20:24412452.

    • Search Google Scholar
    • Export Citation
  • 182.

    ThomasM. Health-related quality of life for those with myelodysplastic syndrome: conceptualization, measurement and implications. In: GreenbergPL ed. Myelodysplastic Syndromes: Clinical and Biological Advances. Cambridge, England: Cambridge University Press; 2006:263295.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 153 153 18
PDF Downloads 25 25 4
EPUB Downloads 0 0 0